Journals / Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları / 2021 / Cilt: 5 - Sayı: 2

Retrospective Analysis of Extranodal Involvement of Head and Neck Diffuse Large B Cell Lymphomas and Comparison of Nodal Disease

Ekstranodal Baş Boyun Diffüz Büyük B Hücreli Lenfomalarının Geriye Yönelik Olarak Değerlendirilmesi ve Nodal Hastalık ile Karşılaştırılması

Pages
21–26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: We aimed to analyze and to compare the patients diagnosed with diffuse large B cell lymphoma (DLBCL) from nodal or extranodal head and neck involvement as clinicopathologic features and overall survival rates.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to analyze and to compare the patients diagnosed with diffuse large B cell lymphoma (DLBCL) from nodal or extranodal head and neck involvement as clinicopathologic features and overall survival rates.
📊
Key Findings & Data:Patients and Methods: We included 52 adult patients who presented with primarly nodal or extranodal head and neck region DLBCL in the study.
💡
Conclusion & Impact:Hence extranodal involvements which are limited to head and neck except central nervous system can be approved of a better prognostic factor.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to analyze and to compare the patients diagnosed with diffuse large B cell lymphoma (DLBCL) from nodal or extranodal head and neck involvement as clinicopathologic features and overall survival rates. Patients and Methods: We included 52 adult patients who presented with primarly nodal or extranodal head and neck region DLBCL in the study. Patients’ demographic, clinical, pathology and imaging data, treatment, response to treatment and prognostic indexes were evaluated. Follow up and survival status were reviewed. Results: 24 patients were included into extranodal group while 28 patients in nodal group. Regarding gender, age, Ki67 profliferation index, BCL-2 positivity, presence B symptoms, performance status, LDH, prognostic indexes, response to 1st line treatment there were not a difference when compared nodal and extranodal groups. Germinal center B cell like origin, BCL-6 positivity and early stage of the disease were higher in extranodal group and these differences were statistically significant (p values are 0.010, 0.016, 0.001, respectively). The distribution of extranodal involvements were as tonsillery (n: 10), thyroid (n: 5), nasopharynx (n: 2), maxillary sinus (n: 2), parotid gland (n: 2), nasal (n: 1), tongue (n: 1) and buccal mucosa (n: 1). The median survival time was 37 months in nodal group and was 43 months in extranodal group. This difference was statistically significant (p value 0.022). Conclusion: The site and the number of the extranodal involvement of DLBCL determines the prognosis of the disease. In our study, we conclude that being the cell of the origin toward to germinal center B like, the chance of earlier detection and treatment of extranodal involvement of this region due to symptoms and being visual earlier than nodal involvement render better survival in the head and neck extranodal DLBCL. Hence extranodal involvements which are limited to head and neck except central nervous system can be approved of a better prognostic factor.

Özet

Amaç: Baş boyun bölgesinden nodal veya ekstranodal tutulumlu diffüz büyük B hücreli lenfoma (DBBHL) tanısı alan hastaların klinikopatolojik özellikleri ve toplam sağkalım oranlarını incelemeyi ve karşılaştırmayı amaçladık. Hastalar ve Yöntem: Çalışmaya primer baş boyun bölgesi ekstranodal veya nodal tutulum ile başvuran DBBHL tanılı 52 erişkin hasta alındı. Hastaların demografik, klinik, patoloji, görüntüleme, tedavi, tedavi cevabı ve prognostik indeksleri değerlendirildi. İzlem ve sağkalım sonuçları gözden geçirildi. Bulgular: Hastaların 24’ü ekstranodal, 28’i ise nodal gruba dahil edildi. Nodal ve ekstranodal gruplar karşılaştırıldığında cinsiyet, yaş, Ki67 proliferasyon indeksi, BCL-2 pozitifliği, B semptom varlığı, performans durumu, LDH, prognostik indeksler, 1. basamak tedaviye yanıt açısından fark yoktu. Ekstranodal grupta germinal merkez benzeri B hücre kökeni, BCL-6 pozitifliği, erken evre hastalık nodal gruba göre daha yüksek oranda bulundu ve bu yükseklik istatistiksel olarak anlamlı saptandı (p değerleri sırasıyla 0.010, 0.016, 0.001). Ekstranodal tutulumların dağılımı tonsil (n: 10), tiroid (n: 5), nazofarenks (n: 2), maksiller sinüs (n: 2), parotis bezi (n: 2), nazal (n: 1), dil (n:1) ve bukkal mukoza (n: 1) şeklindeydi. Ortanca sağkalım nodal grupta 37 ay, ekstranodal grupta 43 ay idi. Bu farklılık istatistiksel olarak anlamlıydı (p= 0.022). Sonuç: Ekstranodal tutulum yeri ve sayısı DBBHL’de prognozu belirlemektedir. Çalışmamızda, baş boyun bölgesi primer ekstranodal DBBHL’lerin kökeninin germinal merkez B benzeri hücre yönünde olmasının, semptomların ve görünürlüğünün nodal olanlara göre daha erken olmasının ve dolayısıyla erken tanı ve tedavi şansının olmasının daha iyi sağkalıma neden olduğu sonucuna vardık. Bu nedenle santral sinir sistemi hariç baş boyun bölgesine sınırlı ekstranodal tutulumlar daha iyi bir prognostik belirteç olarak kabul edilebilir.

🔖

Cite This Article

KIRKIZLAR, H., KIRKIZLAR, T. A., DEMİRCİ, U., GÜLSARAN, S. K., BAŞ, V., ÜMİT, E., DEMİR, A. (2021). Retrospective Analysis of Extranodal Involvement of Head and Neck Diffuse Large B Cell Lymphomas and Comparison of Nodal Disease. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, Cilt: 5 - Sayı: 2, 21–26. https://ajindex.com/articles/417046

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110(2):695-708
  2. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin’s lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997;8:727-37
  3. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet 2017;390(10091):298-310
  4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein, H, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (4th edition). Lyon: IARC Press, 2008
  5. Raghoebier S, Kramer MH, van Krieken JH, Jong D, Limpens J, Kluin-Nelemans JC, et al. Essential differences in oncogene involvement between primary nodal and extranodal large cell lymphoma. Blood 1991;78(10):2680-5 6. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JHJM, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92(9):3152-62
  6. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F. Primary extranodal non-Hodgkin’s lymphomas. Part 2: head and neck, central nervous system and other less common sites. Ann Oncol 1999;10(9):1023-33
  7. Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation- a population-based study of 1575 cases. Br J Haematol 2004;124(2):151-9
  8. Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012;118(17):4166-72. 10. de Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Briere J, et al. Diffuse large B-cell lymphoma of Waldeyer’s ring has distinct clinicopathologic features: a GELA study. Ann Oncol 2012;23(12):3143-51
  9. Validire P, Capovilla M, Asselain B, Kirova Y, Goudefroye R, Plancher C, et al. Primary breast non-Hodgkin’s lymphoma: a large single center study of initiaL characteristics, natural history, and prognostic factors. Am J Hematol 2009;84(3):133-9
  10. Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the surveillance, epidemiology and end results database. Am J Hematol 2014;89(3):3